开始
Investor4321

RCUS 50+% Potential Gains Friday, January 15-17

Arcus Biosciences, Inc. (NYSE:RCUS)  
Investor4321  
NYSE:RCUS   Arcus Biosciences, Inc.
Fundamental Analysis
3
0
fundamental
RCUS releases phase one clinical trial data for a drug they are developing to treat pancreatic cancer on Friday, January 15-17. Look to buy about a week in advance.
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。